Investigating the Impact of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

Faculty Mentor

David Daberkow

Presentation Type

Oral Presentation

Start Date

5-7-2024 12:50 PM

End Date

5-7-2024 1:10 PM

Location

PAT 328

Primary Discipline of Presentation

Biology

Abstract

Investigating the Impact of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

Jair E. Alvarez Jr., Dr. David Daberkow

Department of Biology, Eastern Washington University

Oxytocin is a treatment for PTSD. Previous research suggests that pre-treatment of intranasal oxytocin attenuates signs of fear in rats; however, the impact of intraperitoneal (i.p) oxytocin pre-treatment on signs of fear in rats is unknown. We investigated the effects of i.p. oxytocin pre-treatment on signs of fear. Male Sprague-Dawley rats were divided into 5 groups, (n=8 per group); 1.) controls (vehicle and no foot shock), 2.) shock (vehicle and foot shock), 3.) low dose (0.03 mg/kg oxytocin and foot shock), 4.) medium dose (0.3 mg/kg oxytocin and foot shock), and 5.) high dose (1.0 mg/kg oxytocin and foot shock). Rats were treated with oxytocin (or vehicle) 30 min prior to fear conditioning. Day 1, rats were placed in fear-conditioning chamber which delivered five foot shocks at an intensity of 0.6 mA to the metal grate floor. Day 2, the rats were re-exposed to chamber for 5 minutes, not shocked, and freezing time was recorded via a motion detector. Day 3, rats were re-exposed to chamber for 5 min and shocked again with the same parameters. Day 4, rats were re-exposed to the chamber for 5 min, not shocked, and freezing time was recorded. Preliminary data suggests that the low dose of oxytocin (0.03mg/kg) decreases freezing relative to the untreated shock group. An additional day of shock showed a significant decrease in freezing with the high dose (1.0mg/kg). These data suggest that oxytocin, administered i.p., can be used as a prophylactic pre-treatment to mitigate signs of fear.

This document is currently not available here.

Share

COinS
 
May 7th, 12:50 PM May 7th, 1:10 PM

Investigating the Impact of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

PAT 328

Investigating the Impact of Pretreatment Intraperitoneal Oxytocin on Signs of Trauma

Jair E. Alvarez Jr., Dr. David Daberkow

Department of Biology, Eastern Washington University

Oxytocin is a treatment for PTSD. Previous research suggests that pre-treatment of intranasal oxytocin attenuates signs of fear in rats; however, the impact of intraperitoneal (i.p) oxytocin pre-treatment on signs of fear in rats is unknown. We investigated the effects of i.p. oxytocin pre-treatment on signs of fear. Male Sprague-Dawley rats were divided into 5 groups, (n=8 per group); 1.) controls (vehicle and no foot shock), 2.) shock (vehicle and foot shock), 3.) low dose (0.03 mg/kg oxytocin and foot shock), 4.) medium dose (0.3 mg/kg oxytocin and foot shock), and 5.) high dose (1.0 mg/kg oxytocin and foot shock). Rats were treated with oxytocin (or vehicle) 30 min prior to fear conditioning. Day 1, rats were placed in fear-conditioning chamber which delivered five foot shocks at an intensity of 0.6 mA to the metal grate floor. Day 2, the rats were re-exposed to chamber for 5 minutes, not shocked, and freezing time was recorded via a motion detector. Day 3, rats were re-exposed to chamber for 5 min and shocked again with the same parameters. Day 4, rats were re-exposed to the chamber for 5 min, not shocked, and freezing time was recorded. Preliminary data suggests that the low dose of oxytocin (0.03mg/kg) decreases freezing relative to the untreated shock group. An additional day of shock showed a significant decrease in freezing with the high dose (1.0mg/kg). These data suggest that oxytocin, administered i.p., can be used as a prophylactic pre-treatment to mitigate signs of fear.